medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Title: Aptima Combo2-avoiding variants detected in cervical and endometrial specimens from a cohort of sexually active cisgender women during 16S microbiome profiling.

Authors: Sangmi Jeong[1], Tammy Tollison[1], Hayden Brochu[1], Hsuan Chou[1], Tammy Yu[2], Priyanka Baghaie[2], Kacy S. Yount[2], Toni Darville[2], Xinxia Peng[1] and Catherine M. O'Connell[2]

[1]North Carolina State University

[2]University of North Carolina at Chapel Hill

Correspondence: Catherine O'Connell, PhD, University of North Carolina at Chapel Hill, 8340B MBRB, CB# 7509, 111 Mason Farm Road, Chapel Hill, NC 27599-7509, phone (919) 962-3422, fax:(919) 966-7277, catherine.oconnell@unc.edu

Alternate corresponding author: Xinxia Peng, PhD, North Carolina State University, Raleigh, NC 27695, phone (919) 515-4481, fax: (919)-513-6464, xpeng5@ncsu.edu

Keywords: NAAT, chlamydia, gonorrhea, microbiome, 16S rRNA, false negative, 23S

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract:

Background: Performance of a 16S rRNA analysis of the cervicovaginal microbiome of 220 participants recruited into the T Cell Response against Chlamydia (TRAC) cohort between February 2011 and August 2014 in Allegheny County, Pennsylvania USA surprisingly detected DNA encoding chlamydial 16S rRNA in samples from seven participants who had tested negatively for *Chlamydia trachomatis* (CT) and DNA encoding gonococcal 16S rRNA from five participants who had tested negatively for *Neisseria gonorrhoeae* (NG) infection with the Aptima Combo2 assay (Hologic).

Methods: We used targeted PCR amplification followed by sequencing to characterize the chlamydial 23S rRNA locus and qPCR to detect gonococcal DNA in residual diagnostic swab eluates or DNA used to generate 16S rRNA libraries.

Results: Discrepant specimens that contained chlamydial DNA carried a diagnostic-avoidant, G1526A variant in the 23S rRNA locus identical to variants previously detected in Finland, Denmark, and the UK. PCR validation of gonococcal DNA was confirmed for all participants who had tested negatively, with stochastic effects consistent with infection levels close to the limit of detection by the diagnostic assay.

Conclusions: These data indicate that this probe-avoidant CT mutant, and possibly others, were circulating in the northeastern US prior to their detection and characterization in 2019 and subsequently. Although infrequent, documentation of false negative results for CT indicates a need for clinicians to consider performance of a second test that uses alternate PCR probes if patients have persistent symptoms or have known contact to an infected sex partner and their initial NAAT is negative.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Introduction:

Performing cross sectional or longitudinal research studies investigating natural immunity or immunopathogenesis of sexually transmitted infections (STI) in humans can be a complex, time consuming and expensive undertaking. Efforts to mine all data associated with infection or disease cohorts are often extensive and protracted. Such is the case for the TRAC (T cell Response Against Chlamydia) cohort, a group of 246 cisgender women at elevated risk for chlamydial infection who enrolled between February 2011 and August 2014 while presenting to the Allegheny County, PA Health Department's Sexually Transmitted Diseases Clinic for STI testing and/or management. The TRAC study sought to profile cell mediated responses associated with protection against ascending *C. trachomatis* (CT) infection or reinfection [1, 2]. Since completion of enrollment, data obtained from participant samples and questionnaire responses have been used to profile antibody [1, 3-5], T cell antigen-specific responses [2], and to determine risk factors for ascending infection. Using modern molecular techniques, we quantified pathogen burden [1, 2], local cytokine secretion [6] and used genetic profiling techniques to search for biomarkers predictive of disease or reinfection risk [7-9]. Secondary investigations have also assessed the impact of *Mycoplasma genitalium* infection in this population [10]. Fundamental to the success of these analyses has been accurate classification of study participants according to infection status at enrollment and during subsequent follow up, so enrollee infection status was assigned according to the outcome of an FDA-approved STI diagnostic NAAT test performed at the study visit, the results of which could be used to inform clinical care. Infrequently, discrepant results were observed between research PCR assays detecting chlamydial loci and results obtained using the Aptima Combo 2® assay (AC2), manufactured by Hologic, Inc., a commercially available nucleic acid amplification test (NAAT) that is widely used to co-detect CT and *Neisseria gonorrhoeae* (NG), targeting 23S ribosomal RNA (rRNA) and 16S rRNA in these bacteria, respectively. However, we could not exclude the

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

possibility of cross-contamination from the environment or chlamydia-infected specimens, particularly with repurposed, reprocessed convenience samples, e.g., leftover transport medium.

The availability of pristine "future use" vaginal swabs collected from the same cohort and stored since enrollment provided an opportunity to reexamine these discrepant results while determining cervicovaginal microbiome profiles that associated with ascending chlamydial infection (unpublished). We performed a 16S rRNA gene genomic DNA based microbiome analysis on the entire cohort and detected chlamydial DNA in samples from seven participants who had tested negatively for CT and gonococcal DNA from five participants who had tested negatively for NG infection clinically. PCR amplification and subsequent sequencing using primers directed against the 23S rRNA locus revealed that some of the specimens contained chlamydial DNA carrying a diagnostic-avoidant single nucleotide polymorphism (SNP) that likely contributed to misclassification. These data indicate that this mutant, and possibly others, were circulating in the northeastern US prior to their detection and characterization in the United Kingdom and Denmark in 2019 and subsequently [11-13]. Although infrequent, documentation of false negative results for CT indicates a need for clinicians to consider performance of a second test that uses alternate PCR probes if patients have persistent symptoms or have known contact to an infected sex partner and their initial NAAT is negative. Discrepant NG detection appeared to reflect very low gonococcal loads that challenged the limit of resolution for the NAAT, indicating the need to consider repeat testing in patients with known exposure.

Methods:

T Cell Response against Chlamydia (TRAC) Cohort (246 participants). This cohort was composed of mainly young (median age, 21 years; range, 18-35 years), single (89%), African American (66%) women at high risk for the acquisition of *C. trachomatis*. Criteria indicating high-risk status

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

included > 3 sexual partners in the previous 6 months, ≤ 14 years of age at sexual debut, history of pelvic inflammatory disease (PID), or presentation to the recruitment site with any of the following: presence of mucopurulent cervicitis on exam, or sexual contact with a partner known to be infected with CT or NG or non-gonococcal non-chlamydial urethritis. Women with a current diagnosis of PID according to the Centers for Disease Control and Prevention guidelines were excluded. Additional exclusion criteria were pregnancy, uterine procedure or miscarriage in the preceding 60 days, menopause, hysterectomy, antibiotic therapy in the preceding 14 days, and allergy to study medications. TRAC participants were enrolled into a longitudinal study designed to investigate T cell responses important for protection from incident chlamydial infection over 12 months of follow-up between February 2011 and August 2014 and were recruited from the Allegheny County Health Department's Sexually Transmitted Diseases Clinic, Magee-Womens Hospital (MWH) Ambulatory Care Clinic, and the Reproductive Infectious Disease Research Unit at MWH in Pittsburgh PA. Participants provided informed consent at the time of enrollment and completed questionnaires regarding obstetric/gynecologic history, behavioral practices, sex exposure, contraceptive methods, and symptoms according to study protocols. Clinical, histological, and microbiological testing was performed, and blood and endometrial samples were obtained after enrollment, after which all participants received single-dose agents for gonorrhea (ceftriaxone, 250 mg intramuscularly) and chlamydia (azithromycin, 1 g orally). Participants in this cohort were assessed for cervical and endometrial infection using Aptima Combo 2 (AC2) (Hologic, Marlborough, MA) NAAT with overall infection rates of 67% and 8.5% for CT and NG, respectively. *M. genitalium* (MG) infection was determined using the Aptima MG NAAT (Hologic).

16S library construction and characterization. Cervicovaginal swab samples available from 246 women enrolled in TRAC [1] were processed for 16S rRNA gene microbiome profiling (unpublished). In brief, cervicovaginal microbial communities present in participant specimens

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

were profiled by sequencing the V4 region of 16S rRNA gene using Illumina sequencing. The 16S rRNA amplicon sequencing data was processed at the level of inferred amplicon sequence variants (ASVs) using USEARCH v11 [14]. The raw sequencing data supporting the conclusions of this article is publicly available at NCBI's Short Read Archive (SRA) under BioProject accession number PRJNA1136868.

PCR template purification from residual diagnostic samples. DNA was extracted as previously published using a Quick-DNA Universal Kit (Zymo Research, Irvine, California, USA) from 100 µL to 300 µL of reserved cervical swab eluates. Chlamydial and/or mycoplasmal loads were measured by quantitative PCR [1] targeting the 16SrRNA gene [15] or the highly conserved MG190 locus [10], respectively. Primers directed against the *parA* pseudogene [16], 16S rRNA and 23S rRNA loci [17] were similarly used to validate and/or quantify NG abundance.

PCR amplification and sequencing of 23S rRNA alleles. Amplification conditions for detection of SNPs in *C. trachomatis* 23S were as described [18]. The melting temperature was raised to 98°C for optimal activation of the high fidelity, proof-reading enzyme Phusion (ThermoFisher). Samples were processed independently in a dedicated PCR hood to minimize risk of cross-contamination during analysis. Two rounds of amplification were required to recover sufficient product which was cleaned and concentrated using a DNA Clean and Concentrate kit (Zymo) before sequencing in forward and reverse directions using V3 region primers [18]. Two patient samples that had tested positively using the AC2 test were also analyzed as controls. Sequences generated via Sanger sequencing were aligned against the published sequence using Clone Manager Professional Version 11 (Sci Ed Software LLC, Westminster, CO). Residual cervical templates were used from profiled participants except for 3-209, for whom only endometrial extracted DNA remained available for analysis.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Statistical analysis. The nonparametric Spearman rank correlation coefficient was calculated to assess the overall correlation between CT 16S rRNA gene DNA copy numbers measured by qPCR and the raw read counts of CT 16S rRNA gene from microbiome sequencing analysis using R function 'cor' [19]. The LOESS (Locally Weighted Scatter-plot Smoother) curve was estimated and plotted using a 'geom_smooth' function of the R 'ggplot2' package with default settings [20]. Abundance of NG-specific ASVs present in libraries from individuals testing positively with AC2 and those who tested negative were compared using a Mann-Whitney test (two tailed).

Results:

Detection of chlamydia-derived amplicon sequence variant (ASV) in 16S libraries derived from vaginal swabs obtained from CT negative TRAC participants. Total DNA was extracted from "future use" vaginal swabs from a total of 246 TRAC participants for inclusion in a 16S rRNA gene-based sequencing analysis of the contribution of the cervicovaginal microbiome to ascending chlamydial infection. Three samples were excluded based on DNA low integrity values after extraction. We also excluded twenty-three samples due to the equivocal results of chlamydial infection at the cervix and/or endometrium from clinical diagnostic testing. The remaining 220 samples were processed using the ASV-level analysis, resulting in 1,990 ASVs detected in total from samples sequenced to the average depth of ~151,000 reads. Taxonomy annotations of ASVs were based on sequence comparison against the 16S rRNA gene reference database RDP version 19 [21] using the SINTAX algorithm [22]. We assessed the concordance of STI detection by examining raw read counts of sexually transmitted pathogen-specific 16S rRNA genes vs infections previously assessed by NAAT diagnostic tests (CT, NG, MG) (**Fig. 1a**) and quantified via qPCR (CT [1], **Fig. 1b**). About 58% (83 of 143) samples from participants testing positively for CT at enrollment had non-zero 16S rRNA gene read counts (**Fig. 1a**). Similarly, 85% (17 of 20) samples from participants tested positively for NG, and 15.8% (6 of 38) samples from MG positive

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

enrollees had non-zero 16S rRNA gene read counts. Overall, there was modest correlation (Spearman = 0.575) between the two CT quantification methods (**Fig. 1b**).

Based on clinical diagnostic results obtained at enrollment, the TRAC participants were classified into three groups: 1) uninfected; 2) Endo- participants with CT infection detected only in their cervical diagnostic swab; 3) Endo+ participants who tested positively for CT in both cervical and endometrial diagnostic samples. No TRAC enrollees were identified who tested positively only in their endometrial biopsy. Comparing ASV abundances between CT-positive (Endo- and Endo+) and CT-negative (control) women, we were surprised to detect 16S ASV within libraries derived from samples from women who had been assigned “uninfected” (N=7) based on the results of NAAT testing (**Fig. 1a**). Furthermore, these results correlated with estimated chlamydial abundance derived from a previously performed quantitative 16S PCR assay (**Fig. 1b** and **Table 1**), suggesting that attributing the original results to external or cross-contamination was incorrect. A review of the participants’ clinical data revealed that they were largely asymptomatic, only one had reported experiencing dysuria, consistent with >10 leucocytes detected per high power field in her urine sample with irregular vaginal bleeding, while one other reported dyspareunia and abnormal vaginal discharge. Clinical findings upon pelvic examination were unremarkable for all. Three of the seven participants within this group reported contact with a CT infected partner in the three months prior to their enrollment but that they had not received treatment.

Table 1. TRAC participants with discrepant clinical and molecular CT detection

Sample ID	Clinical testing (CT, MG, NG)	16S rRNA read counts in ASV analysis	16S qPCR*	
			Cx	Endo
3-101	CT-/MG-/NG-	1	78	919

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

3-144		16	420	87
3-145		146	128800	35
3-148		111	3839	457
3-201		55	1495	721
3-226		31	1640	105
3-209	CT-/MG+/NG-	4	13000	62680

*Chlamydial 16S rDNA copies/swab [1].

In the context of the TRAC cohort, reasons for false negative CT NAAT test results, other than testing failures detected at or during performance e.g., compromised reagents or automated run failure (batch specific), include inadequate sampling at the anatomical site or an unanticipated flaw in the diagnostic test. All NAAT tests were run within temporal parameters appropriate for clinical STI testing, so batch-specific effects did not serve as an explanation for these discrepancies because the participants were not recruited contemporaneously. Testing of an endometrial biopsy might result in a false negative because the entire endometrial lining is not sampled, the amounts of tissue obtained may vary [8], and the region of specimen dedicated to NAAT testing is small [10]. However, cervical testing, particularly when performed by highly trained nurse practitioners, is robust [23, 24]. Several publications from Northern Europe have reported instances of false negative testing specifically associated with the AC2 test [12, 13, 25, 26] arising because of probe-avoidant mutations at the chlamydial 23S rRNA locus [18]. Speculating that this might explain our discrepant results, we attempted to amplify the relevant V3 region from cervically or endometrially derived templates that had been extracted from leftover diagnostic swab eluates. In all instances we were successful using the protocol and primers used by Hokynar et al. [18], further confirming the presence of chlamydial DNA in the clinical samples. We detected a G-A substitution at 1523 in the samples of all seven test-discrepant participants (**Fig. 2**) when these products were sequenced. NAAT positively-testing samples (N=2) from the cohort were wild type at this position (data not shown). These data indicated that at least one probe-avoidant variant of CT was circulating in Allegheny Co. PA between May 2012 and

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

February 2014, the time window between enrollments of our earliest and latest discrepant TRAC participants.

16S rRNA gene microbiome analysis also revealed a total of five participants with discrepant NG AC2 testing enrolled from April 2011 to July 2013 (**Fig. 1A, Table 2**), including one participant, 3-209, who also tested discrepantly for CT (**Table 1**). Clinically, one participant reported mild urinary symptoms with abnormal vaginal discharge and irregular bleeding and one other participant reported bleeding with intercourse. Clinical findings after pelvic examination were noteworthy for bleeding with cervical contact for four of five participants but were otherwise unremarkable. Only one of these participants reported contact with an infected partner within the preceding three months but had not received treatment.

The genus *Neisseria* includes a group of commensal species, *N. subflava*, *N. mucosa*, *N. elongata*, in addition to the important human pathogens, *N. gonorrhoeae* and *N. meningitidis* with the potential for genetic exchange between these naturally competent microorganisms [27] so we initially speculated that the ASV detected lacked discriminatory capacity. However, alignment of the 16S V4 sequence from *N. gonorrhoeae* with the 35 *Neisseria* species included in the RDP v18 database, revealed that ASV ZOtu95, detected in the discrepant samples, was highly specific, aligning with 100% identity between bases 535-787 of the 1544 nucleotide V4 region. This suggested that the 16S ASV detected in libraries generated from the vaginal swabs reflected true gonococcal infection. Next, we compared the number of ZOtu95 reads from discordant individuals with those detected in libraries generated from TRAC participants with concordant NG detection (Table 2) as a surrogate for pathogen load. The number of reads counted in NG+ samples ranged across four orders of magnitude but participant swab samples yielding libraries with ≤6 counts still tested positively via AC2 and no difference was detected between the groups using the non-parametric Mann-Whitney test (P=0.4116). Low levels of infection may have contributed to differential sampling of bacterial populations present at the cervix (diagnostic) and in the vagina

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(16S analysis). Quantifying NG by qPCR in residual template was difficult because of the minimal amount of cervical DNA remaining and the potential for high genetic variability between strains. Using primers that targeted multicopy (16S, 23S rRNA) and single copy (ParA pseudogene) loci, with genomic DNA extracted from *N. gonorrhoeae* strain FA19 as a positive control [28], we performed qPCR on diagnostic swab eluates or the 16S template that remained from discrepant NG+ participants (Table 2). Evaluating the performance of the primer pairs using material obtained from participants testing positively for NG infection, we observed that only 8 of the 17 samples consistently yielded PCR product for all 3 loci, while 6, were positive for 1-2. We were unsuccessful in amplifying material from the remaining 3 samples. Overall, successful amplification of the targets did not reflect abundance of 16S read counts in participants' 16S rRNA libraries. For samples derived from participants who had tested negatively clinically but with ZOtu95 reads detected via 16S rRNA microbiome profiling, all tested positively for at least one multicopy locus.

With no source for cross-contamination available in the lab performing the 16S rRNA analysis, we also looked retrospectively at participant enrollment dates to exclude the remote possibility of cross- or environmental contamination [29] occurring during sample collection or NAAT testing. In only one instance did we observe enrollment of a discrepant NG- (3-121) and a confirmed clinically NG+ participant within the same 48-hour window (3-120). However, the presence of additional, neisserial species ASVs in the library generated from 3-120 only (Table 2), is inconsistent with contamination of the discrepant NG- sample by material derived from this diagnostic swab.

Discussion:

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

This study revealed that non-congruent CT infection outcomes that we detected between clinical diagnostics and 16S analysis for cervicovaginal samples collected from TRAC enrollees are best explained as resulting from false negative NAAT tests. The point mutation in 23S that we detected in discordant TRAC participants has been associated with reduced probe binding with the original AC2 assay. The G1523A variant was detected after clinical samples in the UK were screened for probe-avoiding mutants that might be in circulation [12] and also in Denmark [13]. This is the first report of its detection in the United States although Katz et al., reported other 23S variants that mapped to A1518G or G1526A escaping detection in specimens collected in a five-week window, spanning late 2019 to early 2020 (2 of 401) [30]. Our retrospective analysis suggests that diagnostic-avoidant CT was already circulating in western Pennsylvania, USA by 2012 or possibly earlier. The first participants of the TRAC cohort enrolled in February 2011, but we did not identify diagnostically discordant enrollment samples collected prior to May 2012. Provided that this mutation does not impair chlamydial fitness, it is likely that it continues to circulate. The first 23S SNP variant escaping detection by the AC2 assay, FI-nvCT (C1515T), is still present in Finland at an estimated prevalence of 1.8% [31]. Fortunately, the deficit in the clinical test has been recognized and remediated by the manufacturer via incorporation of an additional chlamydial target [25] to improve reliability.

While discordancy between the clinical diagnostic assay for CT 23S RNA and detection of CT 16S rRNA, whether by qPCR or in the 16S rRNA libraries generated for microbiome analysis was ultimately elucidated by our identification of a genetic variant, the basis for the discrepancy of detection of NG16S ASVs in participant samples from study participants who were diagnosed NG negative via the AC2 assay is not easily explained. The NG probe of the AC2 assay is directed against 16S rRNA and is both sensitive and highly specific [32-34]. Multiplex diagnostic tests have been reported to have high sensitivity and high concordance with standard nucleic acid amplification testing [35, 36] with a 4-in-1 test for CT, NG, *Trichomonas vaginalis*, and *M. genitalium* receiving recent approval by the FDA [37]. False positive results for NG have been

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

obtained arising from recombination between 16S loci of *N. meningitidis*, now recognized as a urogenital pathogen [38-40], and NG [41, 42]. The presence of multiple ribosomal RNA operons in this genus [43] elevates the risk for even rare recombination events to become fixed in the population. Should the inverse recombination event also occur, and NG acquire 16S copies from other neisserial species, this could lead to reduced diagnostic sensitivity, the consequences of which could negatively impact infection control and promote spread of diagnostic-avoidant mutants as was observed with Swedish nvCT [44, 45]. Identification of highly conserved, alternative targets for detection of NG has proven extremely challenging, so it is not surprising that we were unable to positively confirm the presence of genomic DNA in all the samples. However, we were also unable to amplify even multicopy targets from specimens collected from participants that tested positively by clinical NAAT, raising the possibility of low abundance bacteria that are asymmetrically distributed between the cervix and vaginal vault of discrepant enrollees.

Fortunately, study participants of TRAC were not harmed by failure to detect their CT and/or NG infection because all recipients were administered appropriate antibiotic therapy at enrollment regardless of their NAAT-determined infection status. The availability of multiplex STI testing enables pathogen-directed therapies and improved antimicrobial stewardship [46]. Appropriately, health care providers are moving from empiric syndromic treatment of patients at risk for STIs to pathogen-specific treatment guided by results of molecular tests. Although current NAATs are highly accurate, since untreated CT and NG can cause minor or no symptoms in the acute phase, but lead to severe complications of chronic pelvic pain, infertility, and ectopic pregnancy in women, clinicians and health department epidemiologists should remain vigilant for potential CT or NG variants evading current approved NAATs such as detection of negative test results in a recently exposed individual, or a decline in overall rates of infection in a particular geographic location as occurred with Swedish nvCT [44, 45].

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Acknowledgements: We thank the women who agreed to participate in this study; Ingrid Macio, Melinda Petrina, Carol Priest, Abi Jett, and Lorna Rabe under direction of Harold Wiesenfeld and Sharon Hillier, for their efforts in the clinic and the microbiology laboratory; and the staff at the Allegheny County Health Department STD Clinic, for their efforts. We would also like to acknowledge the contribution of Dr. Ian Huntress, who sadly passed away during the performance of these studies.

Financial support: This work was supported by the National Institute of Allergy and Infectious Diseases via U19 AI084024 and R01AI170959.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Bibliography:

1. Russell AN, Zheng X, O'Connell CM, Taylor BD, Wiesenfeld HC, Hillier SL, Zhong W, Darville T: **Analysis of factors driving Incident and ascending infection and the role of serum antibody in *Chlamydia trachomatis* genital tract infection**. *J Infect Dis* 2016, **213**(4):523-531.
2. Russell AN, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Taylor BD, Picard MD, Flechtner JB, Zhong W, Frazer LC *et al*: **Identification of *Chlamydia trachomatis* antigens recognized by T cells from highly exposed women who limit or resist genital tract infection**. *J Infect Dis* 2016, **214**(12):1884-1892.
3. Liu C, Mokashi Neha V, Darville T, Sun X, O'Connell Catherine M, Hufnagel K, Waterboer T, Zheng X: **A machine learning-based analytic pipeline applied to clinical and serum IgG immunoproteome data to predict *Chlamydia trachomatis* genital tract ascension and incident infection in women**. *Microbiol Spect* 2023, **0**(0):e04689-04622.
4. Liu C, Hufnagel K, O'Connell CM, Goonetilleke N, Mokashi N, Waterboer T, Tollison TS, Peng X, Wiesenfeld HC, Hillier SL *et al*: **Reduced endometrial ascension and enhanced reinfection associated with IgG antibodies to specific *Chlamydia trachomatis* proteins in women at Risk for Chlamydia**. *J Infect Dis* 2021.
5. Darville T, Albritton HL, Zhong W, Dong L, O'Connell CM, Poston TB, Quayle AJ, Goonetilleke N, Wiesenfeld HC, Hillier SL *et al*: **Anti-chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti-chlamydia IgG is associated with enhanced risk for incident infection**. *Am J Reprod Immunol* 2019, **81**(5):e13103.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

6. Poston TB, Lee DE, Darville T, Zhong W, Dong L, O'Connell CM, Wiesenfeld HC, Hillier SL, Sempowski GD, Zheng X: **Cervical cytokines associated with *Chlamydia trachomatis* susceptibility and protection**. *J Infect Dis* 2019, **220**(2):330-339.

7. Zheng X, Zhong W, O'Connell CM, Liu Y, Haggerty CL, Geisler WM, Anyalechi GE, Kirkcaldy RD, Wiesenfeld HC, Hillier SL *et al*: **Host genetic risk factors for *Chlamydia trachomatis*-related infertility in women**. *J Infect Dis* 2021, **224**(Supplement_2):S64-s71.

8. Zheng X, O'Connell CM, Zhong W, Nagarajan UM, Tripathy M, Lee D, Russell AN, Wiesenfeld H, Hillier S, Darville T: **Discovery of blood transcriptional endotypes in women with pelvic inflammatory disease**. *J Immunol* 2018, **200**(8):2941-2956.

9. Zheng X, O'Connell CM, Zhong W, Poston TB, Wiesenfeld HC, Hillier SL, Trent M, Gaydos C, Tseng G, Taylor BD *et al*: **Gene expression signatures can aid diagnosis of sexually transmitted infection-induced endometritis in women**. *Front Cell Infect Microbiol* 2018, **8**(307):307.

10. Taylor BD, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Darville T: **Risk factors for *Mycoplasma genitalium* endometritis and incident infection: a secondary data analysis of the T cell Response Against Chlamydia (TRAC) Study**. *Sex Transm Infect* 2018, **94**(6):414-420.

11. Roberts DJ, Davis GS, Cole MJ, Naik D, Maru H, Woodford N, Muir P, Horner P, Simms I, Thickett G *et al*: **Prevalence of new variants of *Chlamydia trachomatis* escaping detection by the Aptima Combo 2 assay, England, June to August 2019**. *Euro Surveill* 2019, **24**(38).

12. Cole MJ, Davis GS, Fifer H, Saunders JM, Unemo M, Hadad R, Roberts DJ, Fazal M, Day MJ, Minshull J *et al*: **No widespread dissemination of *Chlamydia trachomatis* diagnostic-escape variants and the impact of *Neisseria gonorrhoeae* positivity on the Aptima Combo 2 assay**. *Sex Transm Infect* 2022, **98**(5):366-370.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

13. Hadad R, Jensen JS, Westh H, Gronbaek I, Schwartz LJ, Nielsen L, Vang TM, Nielsen R, Weinreich LS, Skov MN *et al*: **A *Chlamydia trachomatis* 23S rRNA G1523A variant escaping detection in the Aptima Combo 2 assay (Hologic) was widespread across Denmark in July-September 2019**. *APMIS* 2020, **128**(6):440-444.

14. Edgar RC: **Search and clustering orders of magnitude faster than BLAST**. *Bioinformatics* 2010, **26**(19):2460-2461.

15. O'Connell CM, Brochu H, Girardi J, Harrell E, Jones A, Darville T, Sena AC, Peng X: **Simultaneous profiling of sexually transmitted bacterial pathogens, microbiome, and concordant host response in cervical samples using whole transcriptome sequencing analysis**. *Microb Cell* 2019, **6**(3):177-183.

16. Hazel A, Ponnaluri-Wears S, Davis GS, Low BS, Foxman B: **High prevalence of *Neisseria gonorrhoeae* in a remote, undertreated population of Namibian pastoralists**. *Epidemiol Infect* 2014, **142**(11):2422-2432.

17. Mitchev N, Singh R, Ramsuran V, Ismail A, Allam M, Kwenda S, Mnyameni F, Garrett N, Swe Swe-Han K, Niehaus AJ *et al*: **Assessment of antibiotic resistance and efflux pump gene expression in *Neisseria gonorrhoeae* isolates from South Africa by quantitative real-time PCR and regression Analysis**. *Int J Microbiol* 2022, **2022**:7318325.

18. Hokynar K, Rantakokko-Jalava K, Hakanen A, Havana M, Mannonen L, Jokela P, Kurkela S, Lappalainen M, Unemo M, Puolakkainen M: **The Finnish new variant of *Chlamydia trachomatis* with a single nucleotide polymorphism in the 23S rRNA target escapes detection by the Aptima Combo 2 test**. *Microorganisms* 2019, **7**(8):227.

19. **R: A Language and Environment for Statistical Computing**. In. Edited by Team RC: R Foundation for Statistical Computing; 2015.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

20. Wickham H: **ggplot: Elegant graphics for data analysis**. New York: Springer-Verlag 2016.

21. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, Brown CT, Porras-Alfaro A, Kuske CR, Tiedje JM: **Ribosomal Database Project: data and tools for high throughput rRNA analysis**. *Nucleic Acids Res* 2014, **42**(Database issue):D633-642.

22. Robert CE: **SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS sequences**. *bioRxiv* 2016:074161.

23. Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB: **Systematic review: noninvasive testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae***. *Ann Intern Med* 2005, **142**(11):914-925.

24. Centers for Disease Control and Prevention: **Recommendations for the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*--2014**. *MMWR Recomm Rep* 2014, **63**(RR-02):1-19.

25. Unemo M, Hansen M, Hadad R, Puolakkainen M, Westh H, Rantakokko-Jalava K, Thilesen C, Cole MJ, Boiko I, Lan PT *et al*: **Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape *Chlamydia trachomatis* variants**. *BMC Infect Dis* 2020, **20**(1):419.

26. Rantakokko-Jalava K, Hokynar K, Hieta N, Keskitalo A, Jokela P, Muotiala A, Jokiranta TS, Kuusela R, Sarkkinen H, Aittoniemi J *et al*: ***Chlamydia trachomatis* samples testing falsely negative in the Aptima Combo 2 test in Finland, 2019**. *Euro Surveill* 2019, **24**(22).

27. Smith NH, Holmes EC, Donovan GM, Carpenter GA, Spratt BG: **Networks and groups within the genus *Neisseria*: analysis of *argF*, *recA*, *rho*, and 16S rRNA sequences from human *Neisseria* species**. *Mol Biol Evol* 1999, **16**(6):773-783.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

28. Abrams AJ, Trees DL, Nicholas RA: **Complete genome sequences of three *Neisseria gonorrhoeae* laboratory reference strains, determined using PacBio single-molecule real-time technology**. *Genome Announc* 2015, **3**(5).

29. Ramsden S, Ovens K, Griffiths J, Muir P, Steele-Nicholson A, Horner PJ: **Environmental contamination by *Chlamydia trachomatis* and *Neisseria gonorrhoeae*: is it time to change our infection control practices? Results of a regional study**. *Sex Transm Infect* 2023, **99**(1):35-40.

30. Katz SS, Danavall DC, Morris MR, Herrod BP, Dale SE, Nye MB, Kersh EN, Kirkcaldy RD, Raphael BH: ***Chlamydia trachomatis* variants escaping detection in the Aptima Combo 2 assay in the United States**. *Sex Transm Dis* 2022, **49**(6):448-452.

31. Puolakkainen M, Mannonen L, Unemo M: **The diagnostic-escape Finnish new variant of *Chlamydia trachomatis* first described in 2019 remains present in Finland three years after the introduction of an updated Aptima Combo 2 assay**. *Clin Microbiol Infect* 2023, **29**(5):658-659.

32. Bristow CC, McGrath MR, Cohen AC, Anderson LJ, Gordon KK, Klausner JD: **Comparative evaluation of two nucleic acid amplification tests for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* at extragenital sites**. *Sex Transm Infect* 2017, **44**(7):398.

33. Golparian D, Tabrizi SN, Unemo M: **Analytical specificity and sensitivity of the APTIMA Combo 2 and APTIMA GC assays for detection of commensal *Neisseria species* and *Neisseria gonorrhoeae* on the Gen-Probe Panther instrument**. *Sex Transm Infect* 2013, **40**(2):175-178.

34. Tabrizi SN, Unemo M, Limnios AE, Hogan TR, Hjelmevoll S-O, Garland SM, Tapsall J: **Evaluation of six commercial nucleic acid amplification tests for detection of *Neisseria gonorrhoeae* and other *Neisseria species***. *J Clinical Microbiol* 2011, **49**(10):3610-3615.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

35. Matysiak C, Cheng A, Kirby JE: **Evaluation of the Abbott Alinity m STI assay for diagnosis of the primary causes of sexually transmitted infections in the United States**. *Pract Lab Med* 2023, **36**:e00332.

36. Kriesel JD, Bhatia AS, Barrus C, Vaughn M, Gardner J, Crisp RJ: **Multiplex PCR testing for nine different sexually transmitted infections**. *Int J STD AIDS* 2016, **27**(14):1275-1282.

37. Administration USFD: **Alinity m CMV Assay - P210022**. In.; 2022.

38. Urra E, Alkorta M, Sota M, Alcalá B, Martínez I, Barrón J, Cisterna R: **Orogenital transmission of *Neisseria meningitidis* serogroup C confirmed by genotyping techniques**. *Eur J Clin Microbiol Infect Dis* 2005, **24**(1):51-53.

39. Katz AR, Chasnoff R, Komeya A, Lee MV: ***Neisseria meningitidis* urethritis: a case report highlighting clinical similarities to and epidemiological differences from gonococcal urethritis**. *Sex Transm Dis* 2011, **38**(5):439-441.

40. Kanemitsu N, Hayashi I, Satoh N, Hayakawa T, Mitsuya H, Hayase Y, Hiramoto K, Kojima M: **Acute urethritis caused by *Neisseria meningitidis***. *Int J Urol* 2003, **10**(6):346-347.

41. Walcher M, Skvoretz R, Montgomery-Fullerton M, Jonas V, Brentano S: **Description of an unusual *Neisseria meningitidis* isolate containing and expressing *Neisseria gonorrhoeae*-specific 16S rRNA gene sequences**. *J Clin Microbiol* 2013, **51**(10):3199-3206.

42. Sukhum KV, Jean S, Wallace M, Anderson N, Burnham CA, Dantas G: **Genomic Characterization of Emerging bacterial uropathogen *Neisseria meningitidis*, which was misidentified as *Neisseria gonorrhoeae* by nucleic acid amplification testing**. *J Clin Microbiol* 2021, **59**(2).

43. Klappenbach JA, Saxman PR, Cole JR, Schmidt TM: **rrndb: the Ribosomal RNA Operon Copy Number Database**. *Nucleic Acids Res* 2001, **29**(1):181-184.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

44. Ripa T, Nilsson P: **A variant of *Chlamydia trachomatis* with deletion in cryptic plasmid: implications for use of PCR diagnostic tests**. *EuroSurveill* 2006, **11**(11):E061109.

45. Unemo M, Seth-Smith HM, Cutcliffe LT, Skilton RJ, Barlow D, Goulding D, Persson K, Harris SR, Kelly A, Bjartling C *et al*: **The Swedish new variant of *Chlamydia trachomatis*: genome sequence, morphology, cell tropism and phenotypic characterization**. *Microbiology*, **156**(Pt 5):1394-1404.

46. Karellis A, Naeem F, Nair S, Mallya SD, Routy JP, Gahagan J, Yansouni CP, Kim J, Pai NP: **Multiplexed rapid technologies for sexually transmitted infections: a systematic review**. *Lancet Microbe* 2022, **3**(4):e303-e315.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2. *Neisseria sp.* transcripts detected by 16S ASV analysis and genes detected by qPCR in diagnostic-discrepant or NG+ TRAC participants.

Sample ID	Diagnostic test		16S rRNA read counts				qPCR†		
	Cervix	Endo	ZOtu95: N_gonorrhoeae	ZOtu141: N_subflava	ZOtu264: N_mucosa	ZOtu1566: N_elongata	16S	23S	ParA
3-121	-	-	130	0	0	0	+	+	-
3-140	-	-	123	0	0	0	+	+	+
3-146	-	-	106	0	0	0	+	+	ND
3-151	-	-	6	0	0	0	+	-	+
3-209	-	-	1	0	0	0	-	+	ND
3-012	+	-	471	0	0	0	+	+	+
3-026	+	-	10	0	0	0	-	-	-
3-052	+	-	10	0	0	0	-	+	-
3-089	+	-	24	0	0	0	-	+	+
3-091	+	-	6	0	0	0	+	+	+
3-112	+	-	1032	0	0	0	+	+	+
3-114	+	-	85	0	0	0	-	-	-
3-120	+	-	19	211	131	0	-	+	-
3-122	+	-	110	0	0	0	+	+	+
3-124	+	-	927	0	0	0	-	+	-
3-133	+	-	3	0	0	0	-	-	-
3-136	+	-	2	0	1	0	+	+	-
3-177	+	-	180	0	0	0	+	+	+
3-208	+	-	1151	0	0	0	-	+	-
3-212	+	-	9	0	0	0	+	+	+
3-223	+	-	206	0	0	0	+	+	+
3-235	+	-	349	0	0	0	+	+	+

†Assay performed with diagnostic swab eluate or vaginal swab template used for 16S rRNA microbiome analysis. ND not done because specimen was insufficient or unavailable.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1. STI-derived 16S transcripts detected in vaginal swabs. a) 16S rRNA gene read counts of STIs stratified by infection status at enrollment. b) Concordance between CT 16S rRNA gene read counts versus CT burden by qPCR, where samples are colored by infection status at enrollment. A LOESS curve is shown in red and Spearman correlation in the bottom-right. CT, *Chlamydia trachomatis*; GC, *N. gonorrhoeae*; MG, *M. genitalium*

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316066; this version posted November 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2. Portion of sequence alignment of V3 amplified PCR products from discrepant TRAC participant specimens revealing a g to a substitution at 1523 in the 23S rDNA locus. PCR products from two representative CT+ samples, as determined by AC2 diagnostic test were wild type at this position (data not shown).